Planning precedent report

Additions, alterations and modifications to the existing and permitted industrial facilities, with a total area of approximately 305.8 sqm (permitted under Reg Ref SD23A/0123) at the Pfizer site in Grange Castle. They include; A. a single storey extension to the link building adjacent to the DS2 building permitted under Reg Ref SD23A/0123. The proposed extension is approximately 240 sqm and approximately 7.9 meters high. B. Demolition of existing single-storey extension approximately 36 sqm and approximately 4.2 meters high and construction of a new single storey extension to the existing Softened Water Building. The proposed extension is approximately 65.8 sqm and approximately 7.2 meters high. C. The works also include modifications to internal roads and pathways, underground utilities, site lighting, internal roads and footpaths and all associated site works. This application consists of a variation to previously permitted development for an activity for which a licence under Part IV of the Environmental Protection Agency Act 1992 (as amended by the Protection of the Environment Act, 2003) is required.

Permission for development consisting of the completion of the development granted permission under Planning Application Reg. Ref. SD16A/0236 subject to the amendments and alterations to the previously approved biopharmaceutical manufacturing facility and warehouse extension and other additional, new development not forming part of SD16A/0236, located at the Pfizer site at Grange Castle Business Park, New Nangor Road; The modifications to the approved development will consist of alterations and modifications to previously approved site buildings and infrastructure required to support the proposed development they include, (a) A 6-level biopharmaceutical manufacturing building sized approximately 30,469sq.m (previously approximately 34,650sq.m) and approximately 35 metres high (previously approximately 28.2m high), with stairwells approximately 38m high, and roof-mounted plant and equipment, including solar panels; Modifications to the existing Development and Manufacturing Facility including elevational alterations and modifications to existing plant and equipment; (b) A single-storey warehouse building extension with high-bay, sized approximately 3,200 square metres (previously approximately 1,142sq.m) and approximately 17.5m high, with roof-mounted plant and equipment, including solar panels; (c) A single-storey pedestrian and materials link sized approximately 1,687sq.m (previously approximately 750sq.m) and approximately 6.95m high; (d) A new, additional 4-level extension to the existing DS1 biopharmaceutical manufacturing building, to accommodate material lifts and storage areas, sized approximately 1,925sq.m and approximately 38.2m high, to the south elevation of the existing building; (e) A new, additional single-storey chiller building sized approximately 395 square metres and approximately 6.25m high, with roof-mounted plant and equipment; (f) A new, additional single-storey plant and utilities building sized approximately 256sq.m and approximately 6.25m high, with roof-mounted plant and equipment; (g) Provision of relocated car park from its previously permitted location at the northeast of the side to a new location to the southeast of the proposed biopharmaceutical facility; including approximately 273 additional car parking spaces, including accessible car parking spaces, electric vehicle charging, motorcycle parking, dedicated car-pooling spaces and cycle parking, all accessed from the internal Grange Castle Business Park roads. Mobility parking is located adjacent and directly north of the proposed facility; (h) A relocated, single-storey security building sized approximately 60 sq.m and 6m high; (i) The proposed site infrastructure includes additional cooling towers/heat exchangers, a tank farm, pipe-bridges, surface water harvest tanks, docks and yard areas, including associated items of plant and equipment, an electric vehicle charging and solar panel substation to service photovoltaic panels over new car parking spaces, photovoltaic solar panels located over new car parking spaces, electrical generators, underground pumping facilities and internal roads and paths, fencing and site lighting, and the use of the existing Pfizer site entrance (Gate No.3) for heavy goods vehicles; (j) The development includes modifications to and the extension of, the existing internal road network within the Pfizer Campus; (k) Proposed new landscaping includes new landscaped and planted areas, replacement and reinforcement of the existing landscaping and modifications to existing berms and perimeter security fencing and gates; (l) Proposed new signage based at ground level and on the building facades on the proposed new production building; (m) The works include temporary contractor compounds, temporary car parking and the temporary use of existing site entrances during construction activities; (n) Proposed new surface water management infrastructure for the site, consisting of underground attenuation systems, rainwater harvest cisterns and distribution pipework; (o) All associated site works including sustainability features described in points (a) to (I); Planning permission for the construction of a temporary contractors car park on land to the west of the Pfizer facility with access off Grange Castle Business Park and the reinstatement of the lands to agriculture after the need for the car park expires; The application is seeking permission of 5 years for the completion of the development granted permission under PA Ref: SD16A/0236 subject to the above amendments and alterations to the previously approved Biopharmaceutical Manufacturing Facility and Warehouse and other additional, new, development not forming part of SD16A/0236; This application consists of a development for an activity for which a licence under Part IV of the Environmental Protection Agency Act 1992 (as amended by the Protection of the Environment Act, 2003) is required; An Environmental Impact Assessment Report (EIAR) accompanies this planning application.

Replacement of existing signs in approved locations including the high level signs on the western elevation of the Drug Substance Building and the northern elevation of the Administration QAQC Building with a halo lit company logo and lettering and a face lit company logo and lettering, respectively; the non­illuminated wall mounted company sign adjacent to the entrance on the northern elevation of the Administration QAQC Building with non-illuminated company logo and lettering; the non-illuminated signs on structures on the verge of the Business Park estate road to the west of the site; and the signage on the approved internally illuminated structure on the verge at the junction of the Business Park estate roads to the north west of the site. The development for retention permission consists of the retention of a non-illuminated sign installed on a structure on the verge of the Business Park estate road to the west of the site; non-illuminated signs installed on the boundary fence adjacent to two of the entrances to the site from the Business Park estate road; non-illuminated traffic direction signs installed on traffic sign poles adjacent to the southern entrance into the site and on the verge of the Business Park estate road to the west of the site; and a wall mounted non-illuminated sign with company logo and lettering adjacent to the entrance on the western elevation to the Central Utility building.

Construction of an internal storage mezzanine, sized 75sq.m with an access stairs, located on the first floor of the existing Central Utility Building (C.B.U.) within an existing storage area. This application consists of a variation to a previous permitted development on an activity for which a licence under Part IV of the Environmental Protection Agency Act 1992 (as amended) is required and full details of the proposed development and its anticipated environmental impacts will be notified to the Environmental Protection Agency.

New external Freezer Plant Platform Structure; single storey MRO Stores building within the existing construction compound; external Data Centre unit to the south of the existing Manufacturing Suites Building; airlock extension & relocated external double emergency exit doors to the south of the existing Manufacturing Suites Building; Pallet Storage building adjacent to the existing Drum Store West building within the Utility Yard and boiler Water Chemical Dosing Unit within the CUB yard and all associated site works.

The development consists of additions, alterations and modifications to the existing and permitted industrial facilities (permitted under Reg. Ref. SD23A/0123) at the Pfizer site in Grange Castle. They include; (a) The relocation of and modifications to the previously permitted photovoltaic solar panel substation, adjacent to the car park at the centre of the site and to the south-east of the DS2 building permitted under Reg. Ref. SD23A/0123. The proposed building is now approximately 41 square metres and approximately 6.3 metres high. (b) The construction of a waste compound office, within the waste compound to the south of the DS2 building, both previously permitted under Reg. Ref. SD23A/0123. The proposed building is approximately 14.4 square metres and approximately 2.85 metres high. (c) Modifications and alterations to the existing access and egress (Pfizer Gate No. 3) from the public road within the Grange Castle Business Park, including installation of new vehicular gate and associated fencing including associated minor alterations to existing adjacent berms and modifications and alterations to the existing public pathway and public cycle lane adjacent to the existing entrance (Pfizer Gate No. 3). (d) The works also include modifications to previously permitted underground utilities, site lighting, internal roads and footpaths and all associated siteworks.